{name}
{subtitle}
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~46 mi. (Craiova, Romania, +137 more cities)
facility
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1101)
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
city
~46 mi. (Craiova, Romania, +92 more cities)
facility
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0248)
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~46 mi. (Craiova, Romania, +105 more cities)
facility
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103)
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~46 mi. (Craiova, Romania, +115 more cities)
facility
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type